Maurie Markman, MD | Authors

Maurie Markman on the Groundbreaking TAPUR Trial

March 15, 2017

In this interview we discuss ASCO's first trial, TAPUR (Targeted Agent and Profiling Utilization Registry), which is examining 17 different commercially available drugs in settings outside of their indication.

Uterine Corpus Tumors

November 01, 2015

Carcinoma of the epithelial lining (endometrium) of the uterine corpus is the most common female pelvic malignancy. Factors influencing its prominence are the declining incidence of cervical cancer, longer life expectancy, and earlier diagnosis.

Neoadjuvant Chemotherapy for Ovarian Cancer: The Debate Reconsidered

September 02, 2008

The question of a well-defined role for the use of neoadjuvant chemotherapy in the treatment of ovarian cancer is recognized to be one of the most hotly debated issues in the management of female pelvic malignancies.[1-3] One group of oncologists would argue that it should be the rare patient (eg, with severe comorbidity) who is not a candidate for an initial attempt at maximal cytoreduction.[1]

Management of Ovarian Cancer

April 01, 2006

Over the past 2 decades, we have seen major progress in the management of women with ovarian cancer, with improvements in both overall survival and quality of life. To truly appreciate this progress, it is important to understand the state of affairs regarding the treatment of ovarian cancer in the early 1980s. This paper will discuss that historical background, describe the increasingly favorable impact of evolving treatment paradigms in ovarian cancer, and note future directions for clinical research in this complex disease process.

Commentary (Markman): Neoadjuvant Chemotherapy for Ovarian Cancer

November 01, 2005

Few would question the statementthat the role of surgery in themanagement of epithelial ovariancancer is unique in solid tumoroncology.

Commentary (Markman): Epidermal Growth Factor Receptor Inhibitors for the Treatment of Epithelial Ovarian Cancer

April 01, 2005

In this well-balanced overview, Dr.Blank and colleagues explore thecurrent status of clinical investigationinto a possible role for inhibitingthe activity of epidermal growthfactors as a management approach inpatients with ovarian cancer.

Commentary (Markman): Myalgias and Arthralgias Associated With Paclitaxel

February 01, 2003

In this review, Dr. Garrison andher colleagues present a generaloverview of the development ofmyalgias and arthralgias associatedwith taxane chemotherapy. As notedby the authors, these side effects oftreatment can be quite distressing,although clearly not life-threatening.Fortunately, only a minority of patientsexperience such severe symptomsthat consideration needs to begiven to discontinuing treatment orsubstantially altering the planned taxanedose and schedule.

Advances in the Treatment of Gynecologic Malignancies

December 01, 2002

In their excellent summary of randomized trials examining the management of cancers of the uterus and ovary, Kim and coauthors highlight a significant and worrisome difference that has developed between the two gynecologic malignancies over the past decade, with regard to the direction of clinical research involving chemotherapy. Although it is recognized that cytotoxic chemotherapy is employed in the majority of women with ovarian cancer at initial diagnosis, whereas such treatment is fortunately only required in a minority of individuals with endometrial cancer, it is unclear why there has been such a major divergence in the drugs and combination regimens currently being evaluated in clinical trials.

Is There a Role for Intraperitoneal Chemotherapy in the Management of Ovarian

January 01, 2001

Phase I and II clinical trial data have demonstrated the safety, pharmacokinetic advantage, and potential for enhanced cytotoxicity associated with the intraperitoneal administration of antineoplastic agents in the